Crossject Société Anonyme (ALCJ.PA)

EUR 2.0

(1.01%)

Revenue Summary of Crossject Société Anonyme

Crossject Société Anonyme's latest annual revenue in 2023 was 145 Thousand EUR , down -84.8% from previous year.
Crossject Société Anonyme's latest quarterly revenue in 2024 Q2 was 4.62 Million EUR , down 0.0% from previous quarter.
Crossject Société Anonyme reported a annual revenue of 954 Thousand EUR in annual revenue 2022, up 4.61% from previous year.
Crossject Société Anonyme reported a annual revenue of 912 Thousand EUR in annual revenue 2021, down -81.17% from previous year.
Crossject Société Anonyme reported a quarterly revenue of 3.09 Million EUR for 2023 Q2, down 0.0% from previous quarter.
Crossject Société Anonyme reported a quarterly revenue of 145 Thousand EUR for 2023 FY, down -84.8% from previous quarter.

Annual Revenue Chart of Crossject Société Anonyme (2023 - 2010)

Historical Annual Revenue of Crossject Société Anonyme (2023 - 2010)

Year	Revenue	Revenue Growth
2023	145 Thousand EUR	-84.8%
2022	954 Thousand EUR	4.61%
2021	912 Thousand EUR	-81.17%
2020	4.84 Million EUR	868.8%
2019	500 Thousand EUR	-79.54%
2018	2.44 Million EUR	-24.43%
2017	3.23 Million EUR	127.34%
2016	1.42 Million EUR	-10.3%
2015	1.58 Million EUR	14.5%
2014	1.38 Million EUR	48.0%
2013	935.92 Thousand EUR	164.76%
2012	353.5 Thousand EUR	-45.62%
2011	650 Thousand EUR	225.0%
2010	200 Thousand EUR	0.0%

Year	Revenue	Revenue Growth
2024 Q2	4.62 Million EUR	0.0%
2023 Q2	3.09 Million EUR	0.0%
2023 FY	145 Thousand EUR	-84.8%
2023 Q4	774 Thousand EUR	0.0%
2022 FY	954 Thousand EUR	4.61%
2022 Q2	454 Thousand EUR	0.0%
2022 Q4	500 Thousand EUR	0.0%
2021 Q4	499.73 Thousand EUR	0.0%
2021 FY	912 Thousand EUR	-81.17%
2021 Q2	412.26 Thousand EUR	0.0%
2020 Q2	1.78 Million EUR	0.0%
2020 Q4	3.05 Million EUR	0.0%
2020 FY	4.84 Million EUR	868.8%
2019 Q4	2.82 Million EUR	0.0%
2019 FY	500 Thousand EUR	-79.54%
2019 Q2	500 Thousand EUR	0.0%
2018 Q2	1.88 Million EUR	0.0%
2018 FY	2.44 Million EUR	-24.43%
2018 Q4	558.85 Thousand EUR	0.0%
2017 FY	3.23 Million EUR	127.34%
2017 Q4	2.34 Million EUR	0.0%
2017 Q2	887 Thousand EUR	0.0%
2016 Q4	696.7 Thousand EUR	0.0%
2016 Q2	726 Thousand EUR	0.0%
2016 FY	1.42 Million EUR	-10.3%
2015 Q4	360.01 Thousand EUR	0.0%
2015 Q2	1.22 Million EUR	0.0%
2015 FY	1.58 Million EUR	14.5%
2014 Q2	534 Thousand EUR	0.0%
2014 FY	1.38 Million EUR	48.0%
2014 Q4	851.14 Thousand EUR	0.0%
2013 Q1	- EUR	0.0%
2013 FY	935.92 Thousand EUR	164.76%
2013 Q4	491.92 Thousand EUR	0.0%
2013 Q3	- EUR	-100.0%
2013 Q2	444 Thousand EUR	0.0%
2012 FY	353.5 Thousand EUR	-45.62%
2012 Q1	88.37 Thousand EUR	0.0%
2012 Q2	88.37 Thousand EUR	0.0%
2012 Q3	88.37 Thousand EUR	0.0%
2012 Q4	- EUR	-100.0%
2011 Q4	88.37 Thousand EUR	-45.62%
2011 FY	650 Thousand EUR	225.0%
2011 Q3	162.5 Thousand EUR	0.0%
2011 Q2	162.5 Thousand EUR	0.0%
2011 Q1	162.5 Thousand EUR	0.0%
2010 Q1	50 Thousand EUR	0.0%
2010 Q4	162.5 Thousand EUR	225.0%
2010 Q3	50 Thousand EUR	0.0%
2010 FY	200 Thousand EUR	0.0%
2010 Q2	50 Thousand EUR	0.0%
2009 Q4	50 Thousand EUR	0.0%

Peer Revenue Comparison of Crossject Société Anonyme

Name	Revenue	Revenue Difference
Safe Orthopaedics SA	5.86 Million EUR	97.526%
Spineway SA	10.51 Million EUR	98.622%
Amplitude Surgical SA	106.01 Million EUR	99.863%
Sartorius Stedim Biotech S.A.	2.77 Billion EUR	99.995%
EssilorLuxottica Société anonyme	25.39 Billion EUR	99.999%
bonyf N.V.	309.37 Thousand EUR	53.131%